Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.09B |
| 2 |
K
Kellanova
K
|
+$912M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$774M |
| 4 |
Wells Fargo
WFC
|
+$717M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$604M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$1.36B |
| 2 |
Canadian Natural Resources
CNQ
|
+$927M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$922M |
| 4 |
Crown Castle
CCI
|
+$857M |
| 5 |
McKesson
MCK
|
+$825M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.44% |
| 2 | Technology | 15.01% |
| 3 | Financials | 11.47% |
| 4 | Consumer Discretionary | 10.69% |
| 5 | Communication Services | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MLNX
301
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $84M | 0.03% |
1,649,000
+820,000
| +99% | +$38.9M |
|
302
Hudbay
HBM
$12B
| $83.7M | 0.03% |
12,736,000
+1,636,000
| +15% | +$12.2M |
|
303
Dine Brands
DIN
$455M
| $83.5M | 0.03% |
1,534,219
-367,301
| -19% | -$23.2M |
|
304
Galicia Financial Group
GGAL
$7.11B
| $82.1M | 0.03% |
2,167,356
+1,170,230
| +117% | +$39.3M |
|
305
LivaNova
LIVN
$4.49B
| $80.9M | 0.03% |
1,650,000
| – | – |
|
306
Toll Brothers
TOL
$14B
| $80.3M | 0.03% |
2,225,000
| – | – |
|
307
ON Semiconductor
ON
$32.6B
| $77.4M | 0.02% |
4,994,382
| – | – |
|
308
ABM Industries
ABM
$2.83B
| $72.6M | 0.02% |
1,665,000
| – | – |
|
309
Vail Resorts
MTN
$5.2B
| $71.2M | 0.02% |
371,181
| – | – |
|
310
Penske Automotive Group
PAG
$14.3B
| $70.4M | 0.02% |
1,503,875
-311,625
| -17% | -$15.9M |
|
311
Rockwell Automation
ROK
$49.6B
| $70.1M | 0.02% |
450,000
| – | – |
|
312
Intercontinental Exchange
ICE
$85.7B
| $67.5M | 0.02% |
1,128,125
| – | – |
|
313
First Hawaiian
FHB
$3.39B
| $66.8M | 0.02% |
2,233,335
| – | – |
|
|
BUFF
314
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
| $66.7M | 0.02% |
2,899,910
| – | – |
|
315
Avient
AVNT
$4.18B
| $66.1M | 0.02% |
1,939,600
| – | – |
|
316
Allegiant Air
ALGT
$2.38B
| $65.6M | 0.02% |
409,578
+70,000
| +21% | +$11.8M |
|
317
Qiagen
QGEN
$9.02B
| $63.2M | 0.02% |
2,051,973
| – | – |
|
|
EMWP
318
DELISTED
Eros Media World PLC
EMWP
| $61.8M | 0.02% |
303,627
+37,090
| +14% | +$8.44M |
|
319
Silicon Laboratories
SLAB
$7.31B
| $61.7M | 0.02% |
838,600
-110,538
| -12% | -$7.73M |
|
320
Bristol-Myers Squibb
BMY
$131B
| $61.2M | 0.02% |
1,125,000
| – | – |
|
321
Edwards Lifesciences
EW
$53.9B
| $61.1M | 0.02% |
1,950,006
-11,059,908
| -85% | -$346M |
|
322
Grand Canyon Education
LOPE
$3.73B
| $60.6M | 0.02% |
846,500
| – | – |
|
|
LGF.A
323
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $60.5M | 0.02% |
2,277,761
-1,102,989
| -33% | -$30.1M |
|
324
State Street
STT
$52.3B
| $59.8M | 0.02% |
751,000
-5,018,006
| -87% | -$398M |
|
325
Wynn Resorts
WYNN
$10.6B
| $59.3M | 0.02% |
517,800
| – | – |
|
Similar funds
Capital Research Global Investors's Q1 2017 Portfolio in Review
As of Q1 2017, Capital Research Global Investors held 457 positions worth $317B, up 2.8% from $308B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Research Global Investors withdrew a net $10.5B in Q1 2017, closing 32 positions and reducing 150 holdings. Its most notable exit was Spectra Energy Corp Wi, an estimated $395M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Technology and Financials.
Against the trend, Capital Research Global Investors opened a new position in TransDigm Group worth $346M.
- Capital Research Global Investors's largest Q1 2017 buy was TransDigm Group: 1,570,000 shares worth $346M.
- Capital Research Global Investors added most to Abbott in Q1 2017, an estimated $1.09B increase.
- Capital Research Global Investors's biggest Q1 2017 reduction was Amgen, cutting an estimated $1.36B.
- Capital Research Global Investors fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $395M.
- Capital Research Global Investors's ten largest holdings make up 24% of its $317B portfolio in Q1 2017.
- Capital Research Global Investors opened 30 new positions and closed 32 in Q1 2017.
- Capital Research Global Investors's portfolio value rose 2.8% quarter-over-quarter to $317B.
Based on Capital Research Global Investors's 13F filing for Q1 2017, filed 15 May 2017.